On 30 May 2021 CinnaGen company announced the start of Phase 2 human clinical trial of its potential COVID-19 vaccine. This vaccine technology was originally developed by Vaxine Pty Ltd under the brand name Covax-19™.
As of June 1st, all the 400 planned volunteers were enrolled in the study and were injected with the first dose of either active vaccine or saline placebo in a 3:1 ratio.
The second dose will be administered with an interval of 21 days and all participants will be followed up for 6 months after the injections. The Iranian Food and Drug Administration (IFDA) approved the initiation of this Phase 2 clinical study.
